by @JTC_PALIdev | Dec 28, 2023 | Press Releases
– Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s and Colitis Foundation – Lead program, PALI-2108 for the treatment of moderate-to-severe...
by @JTC_PALIdev | Nov 10, 2023 | Press Releases
– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment of moderate-to-severe ulcerative colitis (UC) is anticipated to...
by @JTC_PALIdev | Oct 11, 2023 | Press Releases
Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 — Palisade Bio (Nasdaq: PALI), a biopharmaceutical company focused on developing novel therapeutics for serious...
by @JTC_PALIdev | Sep 11, 2023 | Press Releases
Carlsbad, CA, Sept. 11, 2023 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct...
by @JTC_PALIdev | Sep 11, 2023 | Press Releases
Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic...
by @JTC_PALIdev | Sep 7, 2023 | Press Releases
Carlsbad, CA, Sept. 07, 2023 — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional...
